The Partnering Agreements with Genmab report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.
Dealmaking activity rebounds to a year’s high
Dealmaking very active at the start of June with seventy new partnering deals, twelve new M&A deals, and twenty-one financings
Analysis of data from the leading life science deals and alliances intelligence database Current Agreements and recently published Partnering Yearbook 2013 report series, shows that the top twenty partnering deals in the life sciences have a combined value of $20.6 billion
This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in August 2012
This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in May 2012
Sorry, your search returned no results.
Genmab has raised gross proceeds of DKK 998 million ($183 million) following pricing of its previously announced private placement financing.
Novartis, a big pharma company is paying Genmab $2 million up front as part of a biopharma collaboration to develop bispecific antibodies based on the latter’s DuoBody technology against two disease target combinations selected by Novartis